| Gateway Foot And Ankle Center, Plc | |
|
313 N Main St, Suite 1j, Ashland City, TN 37015-1347 | |
| (931) 245-1920 | |
| Not Available |
| Full Name | Gateway Foot And Ankle Center, Plc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 313 N Main St, Ashland City, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760812440 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Gateway Foot And Ankle Center, Plc 647 Dunlop Ln, Suite 209, Clarksville, TN 37040-5165 Ph: () - | Gateway Foot And Ankle Center, Plc 313 N Main St, Suite 1j, Ashland City, TN 37015-1347 Ph: (931) 245-1920 |
News Archive
The development of immunotherapy, which mobilizes the body's own immune system to destroy cancer cells, is one of the greatest advances in cancer treatment, but immunotherapy can cause harm to healthy tissue in some patients.
Several humanitarian groups say that despite the G8's pledge made at the 2009 L'Aquila Summit to provide $22 billion over three years to improve agriculture and food security, "the commitment is about to expire" and "much more needs to be done to end hunger," VOA News reports.
Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
Barr Pharmaceuticals, Inc. has announced that its subsidiary Barr Laboratories, Inc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Pharmacia and Upjohn Company's Dostinex (cabergoline) tablets, 0.5 mg.
› Verified 9 days ago
Gateway Foot And Ankle Center, Plc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 313 N Main St., Suite 1j, Ashland City, TN 37015 Phone: 931-245-1920 |